Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments.

[1]  M. Kerneis,et al.  Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. , 2021, JAMA cardiology.

[2]  K. Murphy,et al.  Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series , 2021, Cardio-Oncology.

[3]  F. Barlesi,et al.  Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis , 2020, Journal for ImmunoTherapy of Cancer.

[4]  A. Cohen-Solal,et al.  Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology , 2020, European journal of heart failure.

[5]  Jeroen J. Bax,et al.  Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC) , 2020, European journal of heart failure.

[6]  E. Lipson,et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors , 2019, Cardiovascular research.

[7]  J. Larkin,et al.  Immune checkpoint inhibitors and cardiovascular toxicity. , 2018, The Lancet. Oncology.

[8]  R. Sullivan,et al.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. , 2018, Journal of the American College of Cardiology.

[9]  M. Giacca,et al.  The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC , 2018, European journal of heart failure.

[10]  G. Varricchi,et al.  Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology. , 2017, Circulation.

[11]  F. Bengel,et al.  Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression. , 2017, JCI insight.

[12]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[13]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[14]  M. Bossard,et al.  Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma , 2015, Journal of Immunotherapy for Cancer.

[15]  D. Mann.  Innate immunity and the failing heart: the cytokine hypothesis revisited. , 2015, Circulation research.